Pulmonary hypertension (PH) is a disease that is strictly defined by having a resting mean
pulmonary artery pressure (mPAP) of 25 mm Hg or greater as measured by right heart …

Pulmonary arterial hypertension (PAH) is a devastating disorder characterized by excessive
proliferation and vasoconstriction of small pulmonary artery vascular smooth muscle cells …

Pulmonary hypertension (PH) is a clinical syndrome that is subdivided into five groups per
the World Health Organization (WHO) classification, based largely on hemodynamic and …

Pulmonary hypertension (PH) is a progressive and often fatal illness presenting with
nonspecific symptoms of dyspnea, lower extremity edema, and exercise intolerance …

Highlights•Bibliometric analysis of data acquired from the Web of Science Core Collection
database were assessed via VOSviewer and CiteSpace.•The current state, emerging trends …

The American College of Chest Physicians (CHEST) has been at the forefront of evidence-
based clinical practice guideline development for more than 2 decades. In 2006, CHEST …

Lung transplantation is an established treatment option that can improve quality of life and
prolong survival for select patients diagnosed with end-stage lung disease. Given the gaps …

Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are leading causes
of morbidity and mortality in systemic sclerosis (SSc). As symptoms are often under-reported …

What is known and objective Two endothelin receptor antagonists, ambrisentan and
bosentan, have been demonstrated to be effective individually compared with placebo in the …

Background Group 3 pulmonary hypertension (PH) encompasses PH owing to lung
diseases and/or hypoxia. Treatment patterns, healthcare resource use, and economic …